Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P49190
UPID:
PTH2R_HUMAN
Alternative names:
-
Alternative UPACC:
P49190; Q8N429
Background:
The Parathyroid hormone 2 receptor (PTH2R) is a pivotal component in the human body, acting as a specific receptor for parathyroid hormone. Its activation through G proteins, which in turn activate adenylyl cyclase, plays a crucial role in various physiological systems, including significant implications in pancreatic function and potential neurotransmitter receptor roles in neurons.
Therapeutic significance:
Understanding the role of Parathyroid hormone 2 receptor could open doors to potential therapeutic strategies, particularly in enhancing pancreatic function and neurological health.